Results of two open-label, multicenter phase II studies of docetaxel, platinum salts, and trastuzumab in HER2-positive advanced breast cancer

Mark D. Pegram, Tadeusz Pienkowski, Donald W Northfelt, Wolfgang Eiermann, Ravi Patel, Pierre Fumoleau, Eleonor Quan, John Crown, Deborah Toppmeyer, Michael Smylie, Alessandro Riva, Sandra Blitz, Michael F. Press, David Reese, Mary Ann Lindsay, Dennis J. Slamon

Research output: Contribution to journalArticle

250 Citations (Scopus)

Abstract

Background: Preclinical data indicate that docetaxel, platinum salts, and the combination of both drugs are highly synergistic with the anti-HER2 antibody trastuzumab. The University of California at Los Angeles-Oncology Research Network (UCLA-ORN) and the Breast Cancer International Research Group (BCIRG) have conducted two phase II studies to evaluate docetaxel and trastuzumab in combination with either cisplatin or carboplatin for the treatment of women with advanced breast cancer that overexpresses HER2. Methods: Each study enrolled 62 patients with HER2-overexpressing tumors. Patients received a median of six cycles of docetaxel at 75 mg/m2 of body surface area and cisplatin (BCIRG 101 study) at 75 mg/m2 or carboplatin (UCLA-ORN study) at AUC = 6 mg/mL · min given on day 1 and then every 21 days. Trastuzumab was given on day 1, cycle 1 (4 mg/kg) and then continued weekly at 2 mg/kg for 1 year or until disease progression. Tumor measurements were obtained at baseline, after three cycles of chemotherapy, and then every 3 months. HER2 gene amplification was determined by fluorescence in situ hybridization. Results: Patient characteristics were comparable between trials with the exception that 15% of the patients in the UCLA-ORN study had received previous adjuvant taxane therapy. Both regimens were well tolerated, with manageable toxicities. Hematologic toxicities were more frequent in patients in the UCLA-ORN study than in patients in the BCIRG 101 study, whereas the reverse pattern was observed for non-hematologic toxicities. One patient in each study developed reversible congestive heart failure. Responses were observed in 49 of 62 patients in the BCIRG 101 study (overall response rate = 79%, 95% confidence interval [CI] = 66% to 89%) and in 34 of 59 evaluable patients in the UCLA-ORN study (overall response rate = 58%, 95% CI = 44% to 70%). Median times to progression were 9.9 months (95% CI = 8.3 to 13.1 months) and 12.7 months (95% CI = 8.6 to 15.5 months) for patients in the BCIRG 101 and UCLA-ORN studies, respectively. Overall response rates were higher and median time to progression was longer in the subset of patients whose tumors harbored HER2 gene amplification. Conclusion: Combinations of docetaxel, a platinum salt, and trastuzumab are feasible and active in patients with advanced breast cancers that overexpress HER2. The BCIRG is conducting ongoing randomized studies of the three-drug combination in both the metastatic and adjuvant settings.

Original languageEnglish (US)
Pages (from-to)759-769
Number of pages11
JournalJournal of the National Cancer Institute
Volume96
Issue number10
StatePublished - May 19 2004
Externally publishedYes

Fingerprint

docetaxel
Platinum
Salts
Breast Neoplasms
Los Angeles
Research
Confidence Intervals
erbB-2 Genes
Gene Amplification
Carboplatin
Drug Combinations
Cisplatin
Trastuzumab

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Results of two open-label, multicenter phase II studies of docetaxel, platinum salts, and trastuzumab in HER2-positive advanced breast cancer. / Pegram, Mark D.; Pienkowski, Tadeusz; Northfelt, Donald W; Eiermann, Wolfgang; Patel, Ravi; Fumoleau, Pierre; Quan, Eleonor; Crown, John; Toppmeyer, Deborah; Smylie, Michael; Riva, Alessandro; Blitz, Sandra; Press, Michael F.; Reese, David; Lindsay, Mary Ann; Slamon, Dennis J.

In: Journal of the National Cancer Institute, Vol. 96, No. 10, 19.05.2004, p. 759-769.

Research output: Contribution to journalArticle

Pegram, MD, Pienkowski, T, Northfelt, DW, Eiermann, W, Patel, R, Fumoleau, P, Quan, E, Crown, J, Toppmeyer, D, Smylie, M, Riva, A, Blitz, S, Press, MF, Reese, D, Lindsay, MA & Slamon, DJ 2004, 'Results of two open-label, multicenter phase II studies of docetaxel, platinum salts, and trastuzumab in HER2-positive advanced breast cancer', Journal of the National Cancer Institute, vol. 96, no. 10, pp. 759-769.
Pegram, Mark D. ; Pienkowski, Tadeusz ; Northfelt, Donald W ; Eiermann, Wolfgang ; Patel, Ravi ; Fumoleau, Pierre ; Quan, Eleonor ; Crown, John ; Toppmeyer, Deborah ; Smylie, Michael ; Riva, Alessandro ; Blitz, Sandra ; Press, Michael F. ; Reese, David ; Lindsay, Mary Ann ; Slamon, Dennis J. / Results of two open-label, multicenter phase II studies of docetaxel, platinum salts, and trastuzumab in HER2-positive advanced breast cancer. In: Journal of the National Cancer Institute. 2004 ; Vol. 96, No. 10. pp. 759-769.
@article{ec0fe245d00444a0adbcaa54e9ae898d,
title = "Results of two open-label, multicenter phase II studies of docetaxel, platinum salts, and trastuzumab in HER2-positive advanced breast cancer",
abstract = "Background: Preclinical data indicate that docetaxel, platinum salts, and the combination of both drugs are highly synergistic with the anti-HER2 antibody trastuzumab. The University of California at Los Angeles-Oncology Research Network (UCLA-ORN) and the Breast Cancer International Research Group (BCIRG) have conducted two phase II studies to evaluate docetaxel and trastuzumab in combination with either cisplatin or carboplatin for the treatment of women with advanced breast cancer that overexpresses HER2. Methods: Each study enrolled 62 patients with HER2-overexpressing tumors. Patients received a median of six cycles of docetaxel at 75 mg/m2 of body surface area and cisplatin (BCIRG 101 study) at 75 mg/m2 or carboplatin (UCLA-ORN study) at AUC = 6 mg/mL · min given on day 1 and then every 21 days. Trastuzumab was given on day 1, cycle 1 (4 mg/kg) and then continued weekly at 2 mg/kg for 1 year or until disease progression. Tumor measurements were obtained at baseline, after three cycles of chemotherapy, and then every 3 months. HER2 gene amplification was determined by fluorescence in situ hybridization. Results: Patient characteristics were comparable between trials with the exception that 15{\%} of the patients in the UCLA-ORN study had received previous adjuvant taxane therapy. Both regimens were well tolerated, with manageable toxicities. Hematologic toxicities were more frequent in patients in the UCLA-ORN study than in patients in the BCIRG 101 study, whereas the reverse pattern was observed for non-hematologic toxicities. One patient in each study developed reversible congestive heart failure. Responses were observed in 49 of 62 patients in the BCIRG 101 study (overall response rate = 79{\%}, 95{\%} confidence interval [CI] = 66{\%} to 89{\%}) and in 34 of 59 evaluable patients in the UCLA-ORN study (overall response rate = 58{\%}, 95{\%} CI = 44{\%} to 70{\%}). Median times to progression were 9.9 months (95{\%} CI = 8.3 to 13.1 months) and 12.7 months (95{\%} CI = 8.6 to 15.5 months) for patients in the BCIRG 101 and UCLA-ORN studies, respectively. Overall response rates were higher and median time to progression was longer in the subset of patients whose tumors harbored HER2 gene amplification. Conclusion: Combinations of docetaxel, a platinum salt, and trastuzumab are feasible and active in patients with advanced breast cancers that overexpress HER2. The BCIRG is conducting ongoing randomized studies of the three-drug combination in both the metastatic and adjuvant settings.",
author = "Pegram, {Mark D.} and Tadeusz Pienkowski and Northfelt, {Donald W} and Wolfgang Eiermann and Ravi Patel and Pierre Fumoleau and Eleonor Quan and John Crown and Deborah Toppmeyer and Michael Smylie and Alessandro Riva and Sandra Blitz and Press, {Michael F.} and David Reese and Lindsay, {Mary Ann} and Slamon, {Dennis J.}",
year = "2004",
month = "5",
day = "19",
language = "English (US)",
volume = "96",
pages = "759--769",
journal = "Journal of the National Cancer Institute",
issn = "0027-8874",
publisher = "Oxford University Press",
number = "10",

}

TY - JOUR

T1 - Results of two open-label, multicenter phase II studies of docetaxel, platinum salts, and trastuzumab in HER2-positive advanced breast cancer

AU - Pegram, Mark D.

AU - Pienkowski, Tadeusz

AU - Northfelt, Donald W

AU - Eiermann, Wolfgang

AU - Patel, Ravi

AU - Fumoleau, Pierre

AU - Quan, Eleonor

AU - Crown, John

AU - Toppmeyer, Deborah

AU - Smylie, Michael

AU - Riva, Alessandro

AU - Blitz, Sandra

AU - Press, Michael F.

AU - Reese, David

AU - Lindsay, Mary Ann

AU - Slamon, Dennis J.

PY - 2004/5/19

Y1 - 2004/5/19

N2 - Background: Preclinical data indicate that docetaxel, platinum salts, and the combination of both drugs are highly synergistic with the anti-HER2 antibody trastuzumab. The University of California at Los Angeles-Oncology Research Network (UCLA-ORN) and the Breast Cancer International Research Group (BCIRG) have conducted two phase II studies to evaluate docetaxel and trastuzumab in combination with either cisplatin or carboplatin for the treatment of women with advanced breast cancer that overexpresses HER2. Methods: Each study enrolled 62 patients with HER2-overexpressing tumors. Patients received a median of six cycles of docetaxel at 75 mg/m2 of body surface area and cisplatin (BCIRG 101 study) at 75 mg/m2 or carboplatin (UCLA-ORN study) at AUC = 6 mg/mL · min given on day 1 and then every 21 days. Trastuzumab was given on day 1, cycle 1 (4 mg/kg) and then continued weekly at 2 mg/kg for 1 year or until disease progression. Tumor measurements were obtained at baseline, after three cycles of chemotherapy, and then every 3 months. HER2 gene amplification was determined by fluorescence in situ hybridization. Results: Patient characteristics were comparable between trials with the exception that 15% of the patients in the UCLA-ORN study had received previous adjuvant taxane therapy. Both regimens were well tolerated, with manageable toxicities. Hematologic toxicities were more frequent in patients in the UCLA-ORN study than in patients in the BCIRG 101 study, whereas the reverse pattern was observed for non-hematologic toxicities. One patient in each study developed reversible congestive heart failure. Responses were observed in 49 of 62 patients in the BCIRG 101 study (overall response rate = 79%, 95% confidence interval [CI] = 66% to 89%) and in 34 of 59 evaluable patients in the UCLA-ORN study (overall response rate = 58%, 95% CI = 44% to 70%). Median times to progression were 9.9 months (95% CI = 8.3 to 13.1 months) and 12.7 months (95% CI = 8.6 to 15.5 months) for patients in the BCIRG 101 and UCLA-ORN studies, respectively. Overall response rates were higher and median time to progression was longer in the subset of patients whose tumors harbored HER2 gene amplification. Conclusion: Combinations of docetaxel, a platinum salt, and trastuzumab are feasible and active in patients with advanced breast cancers that overexpress HER2. The BCIRG is conducting ongoing randomized studies of the three-drug combination in both the metastatic and adjuvant settings.

AB - Background: Preclinical data indicate that docetaxel, platinum salts, and the combination of both drugs are highly synergistic with the anti-HER2 antibody trastuzumab. The University of California at Los Angeles-Oncology Research Network (UCLA-ORN) and the Breast Cancer International Research Group (BCIRG) have conducted two phase II studies to evaluate docetaxel and trastuzumab in combination with either cisplatin or carboplatin for the treatment of women with advanced breast cancer that overexpresses HER2. Methods: Each study enrolled 62 patients with HER2-overexpressing tumors. Patients received a median of six cycles of docetaxel at 75 mg/m2 of body surface area and cisplatin (BCIRG 101 study) at 75 mg/m2 or carboplatin (UCLA-ORN study) at AUC = 6 mg/mL · min given on day 1 and then every 21 days. Trastuzumab was given on day 1, cycle 1 (4 mg/kg) and then continued weekly at 2 mg/kg for 1 year or until disease progression. Tumor measurements were obtained at baseline, after three cycles of chemotherapy, and then every 3 months. HER2 gene amplification was determined by fluorescence in situ hybridization. Results: Patient characteristics were comparable between trials with the exception that 15% of the patients in the UCLA-ORN study had received previous adjuvant taxane therapy. Both regimens were well tolerated, with manageable toxicities. Hematologic toxicities were more frequent in patients in the UCLA-ORN study than in patients in the BCIRG 101 study, whereas the reverse pattern was observed for non-hematologic toxicities. One patient in each study developed reversible congestive heart failure. Responses were observed in 49 of 62 patients in the BCIRG 101 study (overall response rate = 79%, 95% confidence interval [CI] = 66% to 89%) and in 34 of 59 evaluable patients in the UCLA-ORN study (overall response rate = 58%, 95% CI = 44% to 70%). Median times to progression were 9.9 months (95% CI = 8.3 to 13.1 months) and 12.7 months (95% CI = 8.6 to 15.5 months) for patients in the BCIRG 101 and UCLA-ORN studies, respectively. Overall response rates were higher and median time to progression was longer in the subset of patients whose tumors harbored HER2 gene amplification. Conclusion: Combinations of docetaxel, a platinum salt, and trastuzumab are feasible and active in patients with advanced breast cancers that overexpress HER2. The BCIRG is conducting ongoing randomized studies of the three-drug combination in both the metastatic and adjuvant settings.

UR - http://www.scopus.com/inward/record.url?scp=2942691785&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=2942691785&partnerID=8YFLogxK

M3 - Article

C2 - 15150304

AN - SCOPUS:2942691785

VL - 96

SP - 759

EP - 769

JO - Journal of the National Cancer Institute

JF - Journal of the National Cancer Institute

SN - 0027-8874

IS - 10

ER -